Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Capecitabine in combination with Lapatinib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Tykerb (lapatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.
Tykerb (lapatinib) [product monograph]. HC. Health Canada approved lapatinib in combination with capecitabine, for the treatment of patients with metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressed on taxanes and anthracycline before starting this therapy. In addition, patients should have progressed on prior trastuzumab therapy in the metastatic setting.